AI Power in Genomics: November 2024 Edition
Dear subscribers,
Welcome to the November 2024 edition! This month, the long-context biological foundation model ‘Evo’ graced the cover of Science, showcasing the remarkable impact that artificial intelligence can have on bioscience and genetics. As a leading company committed to building core tools and technologies that drive innovation in life science, MGI is also at the forefront of integrating AI into this field. AI, as a powerful tool, has been incorporated not only into MGI's product but also in more areas. Mira, MGI's first AI employee, exemplifies this commitment. MGI believes that AI will empower life sciences research and expand the horizons of discovery for researchers.
Explore other highlights throughout November:
AI Power in Genomics
This month, many of you were impressed by Mira, MGI's pioneering AI employee. As a new member of the MGI family, Mira will be undertaking various responsibilities such as training, product introductions, and making appearances at events.
In November, Mira finished her first international appearance at a meeting in Indonesia. Now she is also a featured guest in the MGI Best series Channel, demonstrating how to operate the MGI products.
??If you haven't met Mira yet, click the link below to learn more about her!
MGI ATOPlex Mycobacterium Tuberculosis Targeted Sequencing Solution
To address the global health threat posed by tuberculosis, MGI was invited as part of the industry delegate for NGS drug resistance surveillance tools to join the side events of the Union World Conference on Lung Health 2024. On November 11, MGI participated in the Tuberculosis Genomics Meeting co-hosted by the Indonesian Ministry of Health and Asia Pathogen Genomics Initiative and presented the MGI ATOPlex Mycobacterium tuberculosis targeted sequencing solution("MGI Atoplex MTB solution").
Based on the unique DNBSEQ technology and innovative platform design, the MGI Atoplex MTB solution aims to streamline the identification and spoligotyping of the Mycobacterium tuberculosis complex, detection of mutations, drug resistance prediction, and evolutionary analysis.
Best Practice Series: DNBelab-D4
The DNBelab-D4 is a powerful sample preparation platform to help researchers carry out sequencing-related research. But how to make the best use of its capabilities? Mira shows us how to operate DNBelab-D4.
The Innovative Approach of Long- and Short-read Sequencing in HIV Research
In a study titled "Characterization of a novel HIV-1 second-generation circulating recombinant form (CRF172_0755) among men who have sex with men in China" published in the Journal of Infection, researchers utilized a combination of long- and short-read sequencing to generate near-full-length genomes (NFLGs) of HIV-1, leading to the discovery of a new circulating recombinant form—CRF172_0755.
Using DNBSEQ-G400 for high-quality short reads and newly released CycloneSEQ-WT02 for long reads, the team achieved a powerful synergy in de novo genome assembly. This dual approach leverages the precision of short reads to correct long reads, creating a clearer, more accurate HIV-1 sequence.
Future of Omics Interviews Series
Mo Li, Associate Professor of Bioscience at King Abdullah University of Science and Technology, shared his research experience related to human stem cells and diseases. Li also discussed his collaborative experience with MGI, emphasizing that MGI's technology helps him obtain and analyze high-quality single-cell data. He expressed optimism about the future developments of MGI.
Radoje Drmanac, CSO of MGI and Co-Founder of Complete Genomics, shared his insights on “SEQ ALL.” He emphasized that various project scenarios demand more specialized technologies and equipment. The MGI’s SEQ ALL integrates both long-read and short-read sequencing technologies, allowing it to comprehensively address the diverse needs of customers and provide one-stop services.
Amit Dutt, a professor from the Department of Genetics at the University of Delhi, shared his insights on utilizing next-generation sequencing platforms and other advanced technologies to study the lung cancer genome in India. He emphasized the unique characteristics of the Indian lung cancer genome, highlighting how this research could lead to deeper exploration and understanding of the differences between cancers, ultimately contributing to improved cancer treatment and care.
Dutt believes that next-generation sequencing technologies, including MGI's DNBSEQ technology, will transform the research methodologies utilized by biologists and clinicians. He is confident that sequencing technology will be crucial in advancing biological science and clinical applications.
领英推荐
The Assessment of Automated Sequencing Library Prep
The article from Lab Manager shared comprehensive insights into automated library preparation in sequencing and introduced the MGISP series automated solutions, which leverage MGI's unique expertise in both sequencing and automation, incorporating innovative technologies that have undergone extensive sample testing and process validation.
Revolutionizing Tuberculosis Diagnostics with Next-Gen Sequencing
Tuberculosis (TB) is the second leading cause of death from a single infectious agent, surpassing HIV/AIDS. In 2022 alone, TB claimed 1.3 million lives, and drug-resistant TB (DR-TB) remains a critical challenge. MGI‘s new whitepaper explores how the synergy between ELITech Group’s ELITe InGenius? technology and MGI’s ATOPlex DNBSEQ? sequencing technology can reshape TB diagnostics.
Celebrating the First Installation of DNBSEQ-G99 in Sri Lanka
MGI is excited to announce the successful installation of Sri Lanka's first DNBSEQ-G99 sequencer at Wish Fertility! With this powerful tool, Wish Fertility will be better equipped to deliver improved fertility solutions.
Explore MGI's Extraordinary Sequencing Technologies and Platforms
Imagine a sequencer that not only sequences but also performs pathological section staining simultaneously. What if it could handle both pathological tissue sectioning and spatial proteomics all in one go? The DNBSEQ-G400RS FluoXpert is an innovative system that goes beyond traditional sequencing. Designed to meet your sequencing and imaging needs, it pairs seamlessly with MGI's newly launched FluoXpert mIF reagent set, allowing for staining of up to 23 markers and cell nuclei.
The DNBSEQ-G99 is a platform engineered for maximum versatility with dual flow cell flexibility and support for diverse applications. With High-quality Q40 Data and onboard bioinformatics, the DNBSEQ-G99 accelerates discovery, delivering results you can trust. Designed for optimal efficiency, the DNBSEQ-G99 combines ultra-fast turnaround times with cost efficiency, empowering labs to achieve high-quality sequencing without compromise.
With the DNBSEQ-T7, we’re pushing the boundaries of multi-omics research, delivering genomics, proteomics, and spatial transcriptomics data - all from one powerful, versatile system. The DNBSEQ-T7 provides researchers with an integrated solution to unlock deeper biological insights faster, making it possible to go beyond traditional genomics. Whether you're mapping genetic mutations, profiling proteins, or exploring spatial gene expression, our platform is built to meet your research demands.
New Sequencing Package to Fight Against Dengue Fever
Dengue fever, a prevalent mosquito-borne disease in tropical and subtropical regions caused by dengue virus, poses a significant public health threat. As prevalence remains high in urban and semi-urban areas worldwide, MGI’s new ATOPlex DENV1-4 Targeted Sequencing Package provides a convenient and powerful tool for timely and precise detection of DENV, crucial for effective outbreak control and management. The package is now available for free trial.
Partnership with Universidad de San Martín de Porres to Strengthen Human Genetics Research
Recently, MGI announced a partnership with Universidad de San Martín de Porres to strengthen human genetics research through the implementation of next-generation genomic sequencing (NGS) technologies in the laboratory of the university's Genetic and Molecular Biology Research Center. We look forward to working with Peruvian scientists to investigate specific Peruvian genetic characteristics for the study of diseases and the development of more precise treatments.
Partnership for Advancing Human Cell Mapping Initiative
Recently, MGI announced a commercial partnership with the Human Cell Atlas (HCA) consortium to further accelerate the human cell mapping initiative. Under this partnership, HCA members will gain enhanced access to MGI’s cost-effective and scalable single-cell and spatial omics solutions. In addition, we’re committed to supporting HCA members with expert guidance in experimental design, assay execution, and bioinformatics to maximize the impact of MGI technologies in their research.
Thank you for reading! Catch us next month and follow us on LinkedIn, X, and YouTube for more of the latest content from MGI. To get more information, please visit the MGI website.
Warmest regards,
The “MGI Newsletter” Editorial Team
Ph.D Student at Baghdad University department of biotechnology, Assistant lecturer at biology department, and URGEN Lab supervisor
3 个月Best of luck